Press Releases

2023

Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of Intermediate Dry AMD
September 25, 2023

Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD
April 12, 2023

Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations
February 10, 2023

2022

Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
April 27, 2022

AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®) as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China
January 3, 2022

View prior press releases